| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d33e45e5cbd64b8b893bd62ee22a85b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56b11188f223710057739fa8dd37776e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2510-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H10-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H20-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H10-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10 |
| filingDate |
2020-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a75e3a28533129b87e0428bc4d9e98ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5db285b92d7e57dd73c1bcd3bcead12 |
| publicationDate |
2022-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022137030-A1 |
| titleOfInvention |
In vitro method for assessing the risk of prostate side effect after treatment by ionizing radiation |
| abstract |
The present invention relates to an in vitro method for assessing the risk of developing side effects after ionizing radiation treatment in a prostate cancer subject, comprising the steps of a) measuring radiation induced T-lymphocytes apoptosis in a sample of the subject; b) determining the presence of urinary toxicity in the patient prior to application of ionizing radiation, and optionally of at least one other clinical parameter, disease parameter or ionizing radiation treatment parameter from the patient, and c) combining the value of the at least one biochemical marker measured in step (a) and a value associated with the at least one clinical parameter, disease parameter or ionizing radiation treatment parameter determined in step (b) in a mathematical function to obtain an end-value. |
| priorityDate |
2019-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |